Is metformin safe and does it improve right ventricular function and metabolism in patients with pulmonary arterial hypertension?
In a single-arm phase II study, metformin was safe in patients with PAH and showed potential mechanistic benefits in right ventricular function and lipid metabolism.
<0.05 for all). In the entire cohort, lipid metabolites were among the most changed by metformin. Conclusions Metformin therapy was safe and well tolerated in patients with PAH in this single-arm, open-label phase II study. Exploratory analyses suggest that metformin may be associated with improved RV fractional area change and, in a subset of patients, reduced RV triglyceride content that correlated with altered lipid and glucose metabolism markers. Registration URL: http://www.clinicaltrials.gov; Unique identifier: NCT01884051.
Brittain et al. (Tue,) studied this question.